



PharmaMar to Present at the SVB Leerink 9th Annual Global Healthcare Conference on February 25th at 09:30 Eastern (15:30 CET)

Madrid, February 13th, 2020.- PharmaMar (MSE:PHM) has today announced that its management team will present and host investors one on one meetings at the SVB Leerink 9th Annual Global Healthcare Conference in New York, NY, on Tuesday, February 25th, 2020, at 09:30 EST (15:30 CET).

A live webcast of the presentation will be available on the Events Calendar section of the Company's website within the Newsroom tab:

<https://pharmamar.com/newsroom/events-calendar/?lang=en>, as well as at <http://wsw.com/webcast/svbleerink34/phm.mc/>. A replay of the presentation will also be available on the Company's website after the event, or by using the same link.

Legal Warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127
Miguel Martínez-Cava – Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464
Phone: +34 918466000

Investor Relations:

José Luis Moreno Martínez-Losa – Capital Markets & Investor Relations Director
investorrelations@pharmamar.com

Phone: +34 914444500



Or please visit our website at www.pharmamar.com